North America Uveitis Treatment Market By Drug Class (Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class) By Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online stores) By Country, Industry Analysis and Forecast, 2019 - 2025

Market Report Description

The North America Uveitis Treatment Market would witness market growth of 4.98% CAGR during the forecast period (2019-2025). Iontophoresis is the use of electric current to help move molecules through the epithelium of the hydrophilic cornea, traditionally the greatest barrier to the penetration of medicines into the eye. It would potentially increase the steroid medication's bioavailability, allowing for significantly reduced dosing frequency and improved effectiveness compared to topical corticosteroids. This procedure has the advantage of not being connected to many of the needle-related complications associated with many local procedures.

Treatment of post-infectious uveitis is a medical problem for ophthalmologists. The eye is a privileged site, preserved by blood ocular barriers that restrict the penetration of systemic antimicrobials into the corresponding segment. Furthermore, intraocularly, topical and subconjunctival treatments are unable to generate adequate concentrations of the medicines. Post-infectious uveitis can result from bacteria, viruses, fungi, or protozoa. The treatment method varies widely depending on the etiology of infections.

Based on Drug Class, the market is segmented into Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online stores. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

Free Valuable Insights: Uveitis Treatment Market in North America is expected to register a CAGR of 4.98% during the forecast period (2019-2025)

The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.

Scope of the North America Uveitis Treatment Market Analysis

Market Segmentation:

By Drug Class

• Anti-inflammatory
• Immunotherapy & Targeted Therapies
• Antimicrobial Drugs
• Other Drug Class

By Disease Type

• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Panuveitis

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online stores

By Country

• US
• Canada
• Mexico
• Rest of North America

Companies Profiled

• AbbVie, Inc.
• Alimera Sciences, Inc.
• Enzo Biochem, Inc.
• Amgen, Inc.
• Bausch Health Companies, Inc.
• Clearside Biomedical, Inc.
• EyePoint Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• TopiVert Ltd.
• Novartis AG